Mice homozygous for the Ipr gene develop autoantibodies and polyclonal B cell activation similar to what is seen in human systemic lupus erythematosus patients. We have previously shown that an lpr-specific intrinsic B cell defect was necessary for autoantibody production in this model. In the current study, we have further defined these autoantibody-producing B cells. Two major subsets of B cells have been described. B-1 cells (CD5 + B cells) can be distinguished from conventional B cells on the basis of phenotype, cytokine secretion, gene expression, anatomical location, and function. In addition, B-1 cells have been implicated in autoimmunity in several routine and human studies. To address the question of which B cell subset produces autoantibodies in Ipr mice, we used immunoglobulin heavy chain (Igh) allotype-marked peritoneal (B-1 cell source) and bone marrow (conventional B cell source) cells from lpr mice to establish B cell chimeras. We used two general approaches. In one, we reconstituted sublethally irradiated mice with B-1 ceils of one allotype and bone marrow cells of another aliotype. In the second method, we suppressed endogenous B cells in neonatal mice with allotTpe-specific anti-IgM antibody, and injected peritoneal ceils of another aI1otype. After antibody treatment was stopped, the mouse's conventional B cells recovered, but the B-1 subset was only reconstituted by the donor. In both types of chimeras, antichromatin, rheumatoid factor, and anti-single stranded DNA (ssDNA) autoantibodies were produced by the conventional B cell bone marrow source. In addition, an age-related decrease in peritoneal B-1 cells was seen, even in unmanipnlated lpr mice. These data show that lpr B-1 cells are not important producers of autoantibodies. Conventional B cells are the source of autoantibodies directed at chromatin, ssDNA, and IgG.
D
istinct subsets of B cells are recognized on the basis of function and cell surface phenotype (1). Those B cells initially characterized by their surface expression of the CD5 antigen, provisionally called B-1 calls (2) , have recently received attention as important autoantibody-producing cells in several human and murine experimental models 0). Call transfer studies using fetal omentum have shown independent development of B-1 and conventional B cells consistent with separate lineages (4) , although other evidence suggests some ongoing interchange between the B-1 and conventional subsets based on phenotypic markers (5) . In addition, B-1 cells can be distinguished from conventional B cells by anatomical localization, gene usage, function, and phenotype (3). B-1 cells are most prominent early in ontogeny and have a restricted tissue distribution and cellular origin (6) (7) (8) (9) (10) . The antibodies produced by B-1 cells are generally of the IgM isotype, lack somatic mutation, and have few to no N regions (3, (11) (12) (13) (14) (15) . Their frequent reactivity with the autoantigens single stranded (ss) 1 DNA, bromelain-treated mouse red blood cells (BrMRBC), and autologous IgG has raised the possibility that autoantibody production in systemic autoimmunity is mainly due to the B-1 cells (16, 17) . In support of this notion, it has been reported that B-1 cells are primarily responsible for the production of KF and polyreactire autoantibodies (13, 14, 17) . Some autoimmune mice, such as motheaten, NZB, and related strains, have elevated levels of this subset (11, 13) , and several autoantibody specificities are secreted by NZB B-1 splenic cells (13) . Autoantibodies to BrMRBC are secreted by splenic and peritoneal B-1 cells in nonautoimmune mice as well (13) . Recently, mice with Coombs autoantibody transgenes have provided the first direct evidence that B-1 cells can produce potentially pathogenic autoantibodies in vivo (18) .
Mice homozygous for the autosomal recessive gene Ipr, recently demonstrated to code for a mutant form of the apoptosis-inducing surface receptor, Fas (19) , develop generalized lymphoproliferation (20) . They also produce a spectrum of autoreactivity that resembles that found in human SLE. Whether their autoantibodies are produced by a discrete B cell subset is unknown. In the current studies, we have investigated the role of B-1 cells in SLE-like systemic autoimmunity in Igh allotype-congenic lpr mouse strains.
Taking advantage of the capability of B-1 cells to self-renew after transfer in vivo (6), we prepared double chimeric Ipr mice in which B-1 and conventional B cells and their antibody products could be readily distinguished using aUotypespecific reagents. We found that the autoantibodies were produced almost entirely by bone marrow-derived conventional B cells. Furthermore, there was an unexpected age-related disappearance of peritoneal B-1 cells both in Ipr chimeras and in unmanipulated Ipr mice.
Materials and Methods
M~ C57BL/6 036), B6.C20, C57BL/6-1pr/lpr (B6/lpr), B6.PD Thy-P/Cy (B6-Thy-l.1), and C57BL/6-1pr/lpr-Igh ~ (B6/Ipr-Igh') mice were raised in our breeding colony. The B6/Ipr strain was originally obtained from The Jackson Laboratory (Bar Harbor, ME), and the B6/Ipr-Igh ~ strain was developed in our laboratory by crossing B6.C20 (obtained from Dr. Gayle Bosma, Institute for Cancer Research, Philadelphia, PA) and B6/Ipr. By 5 mo of age, the B6/Ipr-Igh ~ mice develop autoantibodies to chromatin and to IgG, lymphadenopathy, and splenomegaly (21) . Mice used for peritoneal cell donors were 4-8-wk-old. Bone marrow donors were 6-10-wk-old, and recipients for irradiation chimeras were 6-8-wkold. Animals of one sex were used in individual experiments.
Preparation of Cells.
Femurs and tibias were used as sources of bone marrow cells. Cold medium (RPMI 1640 with 15 mM Hepes, 100 U/m1 penicillin, and 100/~g/ml streptomycin (PenStrep) from the University of North Carolina Cancer Center Tissue Culture Facility) was injected into the marrow cavity, and ceils were washed three times. Peritoneal washout ceils (PerC) were obtained by injecting 4-6 ml of chilled media containing 10% newborn calf sera into the peritoneal cavity. The recovered cells, ,x,60% lymphocytes, were washed twice with serum-free medium.
Preparation of Radiation Chimeras. 1 wk before cell transfer, recipients and donors were bled. Recipients were moved to autoclaved cages in an isolation cubicle, and water was treated with neomycin (0.2% wt/vol). 1 d before transfer, mice received 750 rad of gamma-radiation in a 137Cs gamma cell 40 apparatus (Atomic Energy of Canada, Ltd., Ottawa, Canada) or from a s~7,o source (Atomic Energy of Canada, Ltd.). Ceils were resuspended in serum-free medium, and 107 bone marrow cells mixed with 107 PerC were injected into the tail vein of irradiated recipients (6) .
Neonatal Chimeras. B6/Ipr mice were injected within 1 d of birth with 0.1 mg of anti-IgM b mAb (AF6-78.25), followed by twice weekly injections of 0.2 mg for 1 too. On day 2 or 3 after birth, treated mice were injected intraperitoneally with 3 x 10 ~ PerC from 4-8-wk-old B6/lpr-Igh a donors (22, 23) .
Antibodies. ELISA. Allotype-specific total serum IgG2a and IgM, IgM R.F, IgM and IgG2a anti-ssDNA, and IgG2a antichromatin were measured as previously described (21) . RF and IgG2a anti-ssDNA concentrations were expressed in equivalent dilution factors (EDF), defined by the formula: EDF = (Dilution of standard reference sen which gives the equivalent OD of the test serum) x 106 (21). Table 1 ). In this model, the bone marrow donor should reconstitute the conventional B cell subset, and the peritoneal ceUs should reconstitute the B-1 subset (6) . Adequate chimerism was established by 3 mo after transfer, as both a and b allotypes significantly contributed to total serum IgM (Table 2) . B-1 cells (a allotype) made only a minor contribution to total IgG2a. Two-color flow cytometry showed that virtually all B ceUs in the peripheral blood were derived from the bone marrow (data not shown). All of the antichromatin autoantibody at 3 mo was from the conventional (b allotype) B cell source, as well as most of the IgM RF (Table 2) . At 5 mo after transfer, B-1 cells still contributed significantly to total serum IgM, but essentially all of the autoantibodies came from the conventional B cells.
Results

Conventional B Cells
A reciprocal set of irradiation chimeras gave similar results. (Table 3) . A minor contribution by the B-1 cells to total serum IgG2a was seen. The allotype distribution of autoantibodies measured 2 and 3 mo after transfer indicated that conventional B cells (a allotype) were responsible for the specificities assayed (Table 3 ). In this set of chimeras, consistent with the previous experiment, the B-1 cells (b allotype) made no contribution to antichromatin or RF.
Peritoneal Cell Populations in lpr Irradiation Chimeras Did Not
Show Porsistence of B-1 Cells. In B6 and B6.C20 control mice, CD5-bearing peritoneal B-1 (subset B-la) cells were first identified by double staining for CD5 and IgM (Fig. 1 A, top). This population is also IgM~IgD l~ as is the CD5-B-1 (subset B-lb) "sister population" (Fig. 1 A, bottom) (14, 22, 23) . B6 mice averaged 25%0 CD5+IgM + and 33% IgMhiIgD 1~ peritoneal B-1 cells (n --5; age, 3 too). Control mice of the a allotype, B6.C20, showed 33% CD5 + IgM +, and 55% IgMhiIgDl~ B-1 peritoneal ceils (n = 5; age, 3 mo). In contrast, however, peritoneal cells from a representative irradiation chimera I (B6/lpr host), killed 5 mo after transfer, showed no B-1 cells of either allotype (Fig. 1 B) .
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B Cell Subsets in Ipr Mice Similarly, peritoneal ceils from a representative irradiation chimera II (B6/Ipr-Igh a host) killed 5 mo after transfer showed few B-1 ceils of either aUotype by both criteria used to identify B-1 cells (Fig. 1 C) .
Neonatal Chimeras Paralleled the Remits of the Irradiation Chimeras.
In a second approach to establish B cell chimeras (22, 23) , neonatal B6/lpr mice were treated with anti-IgM b and injected with B6/Ipr-Igh" peritoneal cells from young adults (neonatal chimera III, Table 1 ). In this model, the injected antibody suppresses host B cells. The conventional B cells recover after the treatment is stopped, and the B-1 cell subset is reconstituted by the injected peritoneal population (22, 23) . Suppression of the host IgM-bearing neonatal B calls by anti-IgM b was successful, as assayed by ELISA at 5 wk of age (Table 4) . At 2 mo, both B-1 and conventional B ceils contributed to total serum IgM, but thereafter the contribution of the B-1 ceils (a ailotype) decreased. The IgG2a antichromatin and IgM RF directed against IgG1 ' and IgG2b b were made exclusively by the b allotype, conventional B cells at all time points (Table 4) . Two-color flow cytometric analysis demonstrated that the B-1 cell population was nearly absent from the peritoneal cavity 3 mo after transfer (Fig. 1 D) . Subsequent killing at 8 mo after transfer showed that B-1 cells did not return (data not shown).
Conventional B Cells Produced lgM and lgG2a ssDNA in All
Ipr Chimeras. Since B-1 cells were previously reported to secrete authoantibodies specific for ssDNA (13) , sera from Ipr chimeras were assayed for IgM and IgG2a anti-ssDNA (Table  5) . In all cases, these autoantibodies were made only by conventional B cells.
Normal Chimeric Mice Demonstrated Persistence of the 13-1 Cells
After Transfer. When chimeric mice were set up using normal congenic mouse strains in the same way as I/n" strains described above, transferred peritoneal cells were found to reconstitute a persistent B-1 lineage, as has been reported (6, 9, 22, 23, 33) . Shown in Fig. 2 are representative flow cytometric anal- Table 1 for description of chimeras.
yses of each type of normal chimera (Types IV-VI, Table 1) killed at ',~4-6 mo after transfer, and stained for CD5 and IgM. Double staining with IgD and IgM showed higher numbers of B-1 cells (data not shown). The transferred B-1 cells also were persistently functional in all three types of normal chimeras, as evidenced by their contribution to total serum IgM at 3-5 mo after transfer (Table 6) . (Fig. 6 ). Five chimeras killed 1-3 mo after transfer averaged 0% b allotype normal B-1 cells, and 3% a allotype Ipr B-1 cells.
Intact B6/Ipr and B6/Ipr-Igl~ Mice Showed a Loss of Peritoheal B-1 Cells with
Discussion
Our results demonstrate that B-1 cells were not responsible for producing autoantibodies to chromatin, ssDNA, and IgG in Ipr mice. Two different methods were used to make B call chimeras, such that B-1 and conventional B cell subsets were differentially marked by allotype. In all situations, we found that the conventional B cells were nearly entirely responsible for producing the autoantibodies measured. As autoantibody and Ig production by the conventional B cells increased with age, B-1 cell contribution to IgM decreased or remained constant. The occasional small contribution to RF from B-1 cells at two mo after transfer decreased further with time. B-1 cells in the peritoneal cavity were substantially depleted in all types of Ipr chimeric mice 5 mo after transfer. Our data also showed a time-dependent loss of B-1 cells in unmanipuluted Ipr mice.
Certain evidence had already suggested that B-1 cells might not be involved in autoimmunity in Ipr mice and related models. Monoreactive, high affinity autoantibodies, generally IgG, are produced by the conventional subset, and low affinity, generally IgM polyreactive autoantibodies come from the B-1 subset (36, 37) . Autoantibodies characteristic of Ipr systemic autoimmunity are in most cases IgG and undergo extensive somatic mutation and addition of N regions (38) (39) (40) . Autoantibodies produced by the B-1 cells, in contrast, gener- 75 Reap et al. In contrast to these studies, a recent paper showed that transgenic mice carrying genes encoding antierythrocyte an- Table 1 for description of chimera.
tibodies had B-1 cells that apparently produced pathogenic autoantibodies (18) . Although this model points to the direct involvement of B-1 cells in autoimmune disease, the transgenes encoded IgG anti-self antibodies that are not typical orB-1 cells. These autoantibody-producing B-1 cells may thus not exist naturally and may therefore represent disease-causing cells only in these special circumstances. Also, the model employed and the specificity of autoantibodies were different from those studied in the present report. In other experiments, a 10-100-fold increase in the B-l-related specificities antiBrMRBC and anti-T cell was seen, again using a different technique and measuring different specificities than we employed in the present studies (42) . An alternative possibility to implicate B-1 cells in the pathogenesis of disease was suggested by Shirai et al. (43) . These investigators postulated that IgM B-1 cells in autoimmune NZB mice and related strains switch to pathogenic autoantibody producing cells and lose their CD5 antigen. This scenario, however, can be ruled out in our chimeras, since allotype marked cells were used.
The age-associated disappearance in Ipr mice of peritoneal B-1 cells, seen in chimeras and in unmanipulated mice, is consistent with the lack of significant contribution to autoantibody production by this subset. On the other hand, in the irradiation chimeras (chimeras I and II) but not the neonatal chimera (chimera III), B-1 cells must have persisted somewhere, since their contribution to serum IgM was relatively stable. The failure of lpr B-1 cells to produce autoantibodies thus cannot be entirely a result of their disappearance from the peritoneum, but rather also implies a basic inability of this subset to participate in the lpr syndrome.
The loss of peritoneal B-1 cells could be due to several mechanisms. We did not find a massive increase in other peritoneal cell populations in Ipr mice, so a trivial dilution effect cannot be the major explanation. Our experiments with the cotransfer of normal B-1 cells into an lpr environment point to an extrinsic influence rather than an intrinsic Ipr B-1 cell defect. The lpr T cells could thus suppress the B-1 cells. Alternatively, the regulation of the B-1 cells could be under the control of the conventional lpr B cell. Recently, the disappearance of B-1 cells after treatment with anti-Ibl0 in normal mice was shown to be due to increases in "y-interferon, since cotreatment with anti-~/-interferon prevented B-1 cell loss (44) . We are investigating these as possible mechanisms for loss of B-1 cells in Ipr mice, particularly since some autoimmune strains have increased levels of qc-interferon (45) .
SJL is another mouse strain in which a deficit of B-1 cells correlates with autoimmunity. SJL mice do not produce antiBrMRBC plaque-forming cells in vitro (46) , and phenotypic B-1 cells represent only 1-5% of their peritoneal cells (47) . Furthermore, the SJL strain is unusually susceptible to the induction of certain autoimmune diseases, such as experimental autoimmune encephalomyelitis (48) .
It is tempting, therefore, to speculate that B-1 cells may play some role in maintaining homeostasis of the organism and that the loss of B-1 cells in Ipr mice might in fact contribute to the autoimmune syndrome. Since B-1 cells have been deemed important in idiotypic networks and B cell ontogeny, and because they are increased in neonates (10, 49, 50) , the disappearance of B-1 cells could disrupt the network and release autoreactive clones that are normally held in check by idiotypic-antiidiotypic interactions. It was also recently found that B-1 cells are important producers of 11,10, a cytokine that inhibits production of several T cell cytokines and monokines (51) . Previously, it has been shown that certain B-1 cells produce a helper B cell factor, assigning an additional regulatory function to this subset (52) . B-1 cells may thus participate in the immune response as active, regulatory cells (53) (54) (55) (56) (57) , and may not merely represent a vestigial subset of a more primitive, first line defense. B-1 cells themselves, however, are not responsible for autoantibody production in lpr mice.
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